NIHR Maudsley BRC Blog

Our latest news & events

Professor Peter Goadsby elected to the Royal Society Fellowship

Professor Peter Goadsby, Director of the National Institute for Health and Care Research (NIHR) Wellcome King's Clinical Research Facility has been elected to the Fellowship of the Royal Society, a Fellowship of many of the world’s most eminent scientists and the oldest academy in continuous existence.

By NIHR Wellcome King's Clinical Research Facility at 10 May 2022

Multi-variant vaccine study opens at King's CRF

A new vaccine study which will assess the safety and efficacy of a vaccine will will target multiple variants of the COVID-19-causing Sars-CoV-2 virus - including the current dominant variant Omicron.

By NIHR Wellcome King's Clinical Research Facility at 13 Apr 2022

Novavax COVID-19 jab trialled at King’s CRF approved by UK drugs agency

UK drugs regulator, the Medicine and Healthcare products Regulatory Agency (MHRA) has approved Novavax's Nuvaxovid vaccine, which was trialled at the King's CRF, for use in the UK.

By NIHR Wellcome King's Clinical Research Facility at 16 Feb 2022

Love Your Liver Month

January is Love Your Liver Month! King's College Hospital and the King's CRF are at the forefront of liver research and treatment. For Love Your Liver Month, we provide a snapshot of just some of the exciting research being done at the Trust with support from the King's CRF.

By NIHR Wellcome King's Clinical Research Facility at 24 Jan 2022

Psilocybin, in 10mg or 25mg doses, has no detrimental effects in healthy people

New research from King’s College London, in partnership with COMPASS Pathways and supported by NIHR Maudsley BRC, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants at the same time.

By NIHR Maudsley BRC at 4 Jan 2022